Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984242 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 305
- Enrollment target
NCT01984242 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 305 participants.
The verdict
NCT01984242, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 305 participants
- Enrollment target
Study Summary
This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy either in the adjuvant or metastatic setting.
Interventions
- DRUG Bevacizumab
- DRUG Sunitinib
- DRUG Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2014-01-08 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984242
The ClinicalTrials.gov registry entry for NCT01984242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01984242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984242 about?
NCT01984242 is a clinical study titled "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma". This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who hav...
What is the current status of trial NCT01984242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2014-01-08. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT01984242?
The interventions under investigation include: Bevacizumab (DRUG), Sunitinib (DRUG), Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody (DRUG).
Who is sponsoring clinical trial NCT01984242?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.